Immunometabolic Activation of Invariant Natural Killer T Cells

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Jun 13

PMID 29892305

Citations 14

Authors

Francesca A Ververs

Eric Kalkhoven

Belinda Vant Land

Marianne Boes

Henk S Schipper

Affiliations

Soon will be listed here.

Abstract

Invariant natural killer T (iNKT) cells are lipid-reactive T cells with profound immunomodulatory potential. They are unique in their restriction to lipid antigens presented in CD1d molecules, which underlies their role in lipid-driven disorders such as obesity and atherosclerosis. In this review, we discuss the contribution of iNKT cell activation to immunometabolic disease, metabolic programming of lipid antigen presentation, and immunometabolic activation of iNKT cells. First, we outline the role of iNKT cells in immunometabolic disease. Second, we discuss the effects of cellular metabolism on lipid antigen processing and presentation to iNKT cells. The synthesis and processing of glycolipids and other potential endogenous lipid antigens depends on metabolic demand and may steer iNKT cells toward adopting a Th1 or Th2 signature. Third, external signals such as toll-like receptor ligands, adipokines, and cytokines modulate antigen presentation and subsequent iNKT cell responses. Finally, we will discuss the relevance of metabolic programming of iNKT cells in human disease, focusing on their role in disorders such as obesity and atherosclerosis. The critical response to metabolic changes places iNKT cells at the helm of immunometabolic disease.

Citing Articles

Lipid accumulation in adipose tissue-resident iNKT cells contributes to an inflammatory phenotype.

Morris I, Vrieling F, Bouwman A, Stienstra R, Kalkhoven E Adipocyte. 2024; 13(1):2421750.

PMID: 39484712 PMC: 11540091. DOI: 10.1080/21623945.2024.2421750.

Nutraceuticals as Potential Therapeutic Modulators in Immunometabolism.

Alba G, Dakhaoui H, Santa-Maria C, Palomares F, Cejudo-Guillen M, Geniz I Nutrients. 2023; 15(2).

PMID: 36678282 PMC: 9865834. DOI: 10.3390/nu15020411.

T-cell Metabolism as Interpreted in Obesity-associated Inflammation.

Bharath L, Hart S, Nikolajczyk B Endocrinology. 2022; 163(10).

PMID: 35932471 PMC: 9756079. DOI: 10.1210/endocr/bqac124.

Harnessing immunometabolism for cardiovascular health and cancer therapy.

Markovska A, Schipper H, Boes M Immunother Adv. 2022; 1(1):ltab021.

PMID: 35919737 PMC: 9327100. DOI: 10.1093/immadv/ltab021.

Sortase A-Cleavable CD1d Identifies Sphingomyelins as Major Class of CD1d-Associated Lipids.

Rudolph M, Wang Y, Simolka T, Huc-Claustre E, Dai L, Grotenbreg G Front Immunol. 2022; 13:897873.

PMID: 35874748 PMC: 9301999. DOI: 10.3389/fimmu.2022.897873.

References

Sasset L, Zhang Y, Dunn T, Di Lorenzo A . Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis. Trends Endocrinol Metab. 2016; 27(11):807-819. PMC: 5075255. DOI: 10.1016/j.tem.2016.07.005. View

Barral D, Brenner M . CD1 antigen presentation: how it works. Nat Rev Immunol. 2007; 7(12):929-41. DOI: 10.1038/nri2191. View

Chiu Y, Park S, Benlagha K, Forestier C, Savage P, Teyton L . Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat Immunol. 2001; 3(1):55-60. DOI: 10.1038/ni740. View

Im J, Arora P, Bricard G, Molano A, Venkataswamy M, Baine I . Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity. 2009; 30(6):888-98. PMC: 2719696. DOI: 10.1016/j.immuni.2009.03.022. View

Turpin S, Nicholls H, Willmes D, Mourier A, Brodesser S, Wunderlich C . Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014; 20(4):678-86. DOI: 10.1016/j.cmet.2014.08.002. View

Favreau M, Menu E, Gaublomme D, Vanderkerken K, Faict S, Maes K . Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma. Leukemia. 2017; 31(12):2678-2685. DOI: 10.1038/leu.2017.146. View

Godfrey D, Stankovic S, Baxter A . Raising the NKT cell family. Nat Immunol. 2010; 11(3):197-206. DOI: 10.1038/ni.1841. View

van Eijkeren R, Krabbe O, Boes M, Schipper H, Kalkhoven E . Endogenous lipid antigens for invariant natural killer T cells hold the reins in adipose tissue homeostasis. Immunology. 2017; 153(2):179-189. PMC: 5765379. DOI: 10.1111/imm.12839. View

Ertunc M, Hotamisligil G . Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016; 57(12):2099-2114. PMC: 5321214. DOI: 10.1194/jlr.R066514. View

10.

Wilson S, Kent S, Patton K, Orban T, Jackson R, EXLEY M . Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998; 391(6663):177-81. DOI: 10.1038/34419. View

11.

Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y . The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999; 189(7):1121-8. PMC: 2193012. DOI: 10.1084/jem.189.7.1121. View

12.

Chen X, Wang X, Keaton J, Reddington F, Illarionov P, Besra G . Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules. J Immunol. 2007; 178(10):6181-90. DOI: 10.4049/jimmunol.178.10.6181. View

13.

Lynch L, Nowak M, Varghese B, Clark J, Hogan A, Toxavidis V . Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity. 2012; 37(3):574-87. PMC: 4991771. DOI: 10.1016/j.immuni.2012.06.016. View

14.

Patwardhan G, Beverly L, Siskind L . Sphingolipids and mitochondrial apoptosis. J Bioenerg Biomembr. 2015; 48(2):153-68. PMC: 5434644. DOI: 10.1007/s10863-015-9602-3. View

15.

Cohen N, Brennan P, Shay T, Watts G, Brigl M, Kang J . Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells. Nat Immunol. 2012; 14(1):90-9. PMC: 3764492. DOI: 10.1038/ni.2490. View

16.

Gorini F, Azzimonti L, Delfanti G, Scarfo L, Scielzo C, Bertilaccio M . Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood. 2017; 129(26):3440-3451. DOI: 10.1182/blood-2016-11-751065. View

17.

Meikle P, Summers S . Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol. 2016; 13(2):79-91. DOI: 10.1038/nrendo.2016.169. View

18.

Porubsky S, Speak A, Salio M, Jennemann R, Bonrouhi M, Zafarulla R . Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells. J Immunol. 2012; 189(6):3007-17. PMC: 3442250. DOI: 10.4049/jimmunol.1201483. View

19.

Oki S, Tomi C, Yamamura T, Miyake S . Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int Immunol. 2005; 17(12):1619-29. DOI: 10.1093/intimm/dxh342. View

20.

Van Kaer L, Parekh V, Wu L . Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol. 2012; 34(2):50-8. PMC: 3615427. DOI: 10.1016/j.it.2012.08.009. View